A New Target in the Fight Against Diabetic Eye Disease

Diabetic retinopathy—damage to the blood vessels of the retina caused by persistently high blood sugar—is a serious complication of Type 1 diabetes. It ranks among the leading causes of vision loss for working-age adults, making it a major health concern for the diabetes community.

The disease develops gradually as high blood sugar triggers inflammation and oxidative stress (a type of cellular damage) in the tiny blood vessels that nourish the retina. Over time, this damage weakens the vessels and impairs their function, eventually leading to vision problems.

Scientists have long known that HDAC6, a protein found inside cells, is involved in various cellular processes. In recent years, researchers suspected it might also play a role in vascular damage. However, its specific role in the blood vessels of the eye remained unclear—until now.

This new research zeroes in on HDAC6's function in endothelial cells, the cells that form the inner lining of blood vessels. The team investigated whether removing HDAC6 specifically from these cells could protect against diabetic eye injury.

Researchers created mice with a genetic modification that removed HDAC6 only from their endothelial cells, then induced Type 1 diabetes in these mice using a standard research method. They compared the retinas of these mice to diabetic mice with normal HDAC6 levels.

The results were striking. Diabetic control mice developed typical features of retinopathy: damaged blood vessels, increased inflammation, oxidative stress, aging of endothelial cells, and impaired vision. In contrast, the mice without endothelial HDAC6 were largely protected. Their retinas maintained better vascular integrity, had lower inflammation and oxidative stress, and preserved their normal visual function.

These findings identify endothelial HDAC6 as a critical contributor to the cascade of vascular damage that occurs in diabetic retinopathy.

This discovery opens a new therapeutic avenue. Rather than simply controlling blood sugar—important as that is—drugs designed to block or reduce HDAC6 activity in blood vessel cells might help prevent or slow the microvascular damage that leads to vision loss.

The research was conducted in mice, so it does not yet prove that the same approach would work in humans. However, it provides a clear scientific target for further investigation and drug development aimed at protecting the eyes of people with Type 1 diabetes.

Source: Cells. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.